Implementing Health Technology Assessment in Oman

By João L. Carapinha

May 6, 2025

A recent article titled “A roadmap towards implementing health technology assessment in Oman” outlines a strategy for integrating health technology assessment in Oman into the healthcare system over the next decade. This initiative aims to improve resource allocation and facilitate evidence-based decision-making for health technologies.

Strategic Roadmap for HTA Implementation

Oman is developing a phased plan for health technology assessment (HTA) to tackle rising healthcare costs and new medical technologies. The roadmap features short-term capacity building (1-2 years), medium-term expansion of HTA infrastructure (3-5 years), and long-term comprehensive integration (6-10 years). All these phases aim to create a sustainable, evidence-based healthcare system. For a detailed insight into the HTA approach, refer to the original article here.

Current Status and Future Strategy

The Omani HTA system is in its nascent stages but holds significant potential for growth. A thorough gap analysis comparing the current state with the desired future of HTA shaped the implementation roadmap. This approach uniquely suits the strategy to the Omani healthcare context.

A notable aspect of Oman’s strategy is the establishment of a single centralized HTA unit under the Ministry of Health. This approach contrasts with other Middle Eastern countries that usually have multiple HTA bodies, reflecting strong political commitment.

Phased Approach to Implementation

The roadmap delineates a structured three-phase plan:

Short-term (1-2 years):

  • Capacity-building initiatives through targeted training programs
  • Initial HTA infrastructure focusing on pharmaceuticals with significant budget impact
  • Implementing a preliminary cost-effectiveness threshold based on 1-3× GDP per capita

Medium-term (3-5 years):

  • An expanded HTA unit with a broadened focus on medical devices and surgical interventions
  • Creation of cost-effectiveness thresholds specific to Oman
  • Increased public engagement and awareness regarding HTA

Long-term (6-10 years):

  • Expanding the technology focus to include prevention programs and public health initiatives
  • Publishing comprehensive HTA recommendations and appraisal reports
  • Setting transparent timelines for review activities
  • Revising previous policy decisions based on new evaluations

Aligning HTA with National Vision

The incorporation of HTA in Oman resonates with the broader goals of “Oman Vision 2040.” This vision aspires to create a transparent healthcare system that promotes equity and delivers high-quality services. It emphasizes sustainable funding for health initiatives and encourages leadership in scientific research.

In parallel, the European Union is advancing HTA implementations, with new regulations enacted in January 2025. These regulations aim to transform the evaluation of medicines and health technologies.

Similar challenges in HTA implementation are evident globally. A review by the World Health Organization underscores that effective HTA requires robust political commitment, ongoing funding, and integration with health information systems. Oman’s current e-health strategy lays a solid foundation for gathering patient data essential for HTA activities. However, adjustments will be necessary to fully meet HTA requirements.

Economic Implications and Outcomes Research

Enhancing Economic Efficiency

The rollout of HTA in Oman is poised to enhance efficiency in healthcare spending. Presently, about 5.3% of GDP is allocated to healthcare. HTA will optimize resource allocation amid projected increases in healthcare expenditures. The roadmap’s initial focus on high-budget pharmaceuticals exemplifies a prudent strategy.

Transforming Market Access and Reimbursement

The introduction of HTA will alter the processes for health technologies gaining market access in Oman. Manufacturers will be required to:

  • Create evidence packages aligning with Omani standards
  • Adapt to new submission criteria and timelines
  • Engage in potential price negotiations tied to cost-effectiveness evaluations

The establishment of multiple cost-effectiveness thresholds will facilitate more organized reimbursement decisions. Including multi-criteria decision analysis (MCDA) allows for evaluating factors beyond cost-effectiveness.

Regional Collaboration and Influence

As Oman advances this roadmap, it may serve as a model for HTA development in the Gulf Cooperation Council (GCC) region. The study discusses plans for collaborative efforts via the GCC and Gulf Health Council.

Ultimately, the success of Oman’s centralized HTA model could inspire other countries with similar healthcare frameworks.

This roadmap marks a pivotal shift towards evidence-based healthcare decision-making in Oman. By recognizing implementation challenges while establishing clear milestones, Oman is poised for significant advancement in healthcare delivery.

Reference url

Recent Posts

Medical Device Innovation South Africa: Breaking Down Systemic Barriers

By HEOR Staff Writer

April 27, 2026

Medical device innovation South Africa is hindered by deep structural obstacles that prevent locally developed technologies from reaching patients, despite the country’s considerable technical expertise. South Africa’s medical technology sector remains trapped in a cycle of heavy import dependenc...
Expanding Access to Hormonal IUDs in South Africa through Generic Innovation
The launch of AVIBELA marks a significant milestone for hormonal IUD South Africa, introducing the country’s first generic levonorgestrel 52 mg intrauterine device. Developed by Medicines360 and commercialized in partnership with Pharma Dynamics, AVIBELA is more than 99% effective at preventing p...
Europe Pharmaceutical Access at a Critical Crossroads Amid U.S. Pricing Policies

By João L. Carapinha

April 23, 2026

Europe Pharmaceutical Access is at a “very critical point,” according to Emer Cooke, Executive Director of the European Medicines Agency (EMA). The number of new drug launches in Europe has fallen by more than a third since U.S. President Donald Trump’s “most-favored-nation” (MFN) drug pricing po...